Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 open‑label dose‑finding study of BAY 2599023 (DTX201) gene therapy in adults with severe hemophilia A
2023-505827-29-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Oct 2018
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of peboctocogene camaparvovec in hemophilia A, sponsored by Bayer. Primary endpoint: Safety and tolerability (adverse events). Started Oct 2018; status: completed.
02
Drugs
peboctocogene camaparvovec
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2023-505827-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505827-29-00.